all report title image

INSULIN MARKET ANALYSIS

Insulin Market, by Product Type (Drugs (Rapid Acting (Humalog, Novolog, and Apidra), Short Acting (Novolin R and Humulin R), Intermediate Acting (Humulin N and Novolin N), Long Acting (Levemir, Degludec, Lantus, and Basaglar), Premixed (Humalog Mix and Novolog Mix)) and Drug Delivery Devices (Pens and Syringes)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)), and By Region - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

  • To Be Published : Nov 2024
  • Code : CMI2183
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Leading Companies

Global Insulin Market – Competitive Landscape

Key players operating in the global insulin market include Eli Lilly and Company, Novo Nordisk A/ S, Julphar Gulf Pharmaceutical Industries, Sanofi S.A., Biocon Limited, GlaxoSmithKline, and Wockhardt. These companies are adopting strategies such as mergers, acquisitions, expansions, collaborations, and new product launches to retain their position in the global insulin market. For instance, in August 2018, Novo Nordisk acquired Ziylo to develop smart, glucose responsive insulin (GRIs), ensuring optimal glucose control and reducing risk of hypoglycemia.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.